MaryMahoneyRuisiMD

PubMed

• 12 citations
  Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.
  David M Loeb, Daniel A Morgenstern, Yvan Samson, Anne Uyttebroeck, Chuhl Joo Lyu, An Van Damme, Karsten Nysom, Margaret E Macy, Alexandra P Zorzi, Julia Xiong, Petra P...> ;Cancer Immunology, Immunotherapy. 2022 Oct 1
• 1 citations
  Long-term avelumab in advanced non-small-cell lung cancer: summaries andanalyses from JAVELIN Solid Tumor.
  Borys Hrinczenko, Nicholas Iannotti, Sanjay Goel, David Spigel, Howard Safran, Matthew H Taylor, Jaafar Bennouna, Deborah J Wong, Karen Kelly, Claire Verschraegen, Mar...> ;Future Oncology. 2022 Apr 1
• 12 citations
  Reduced expression of annexin A2 is associated with impaired cell surface fibrinolysis and venous thromboembolism
  Hannah Fassel, Huigen Chen, Mary M. Ruisi, Neha Kumar, Maria T. DeSancho, Katherine A. Hajjar> ;Blood. 2021 Apr 22
• 2 citations
  Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from th...
  Keunchil Park, Mustafa Ozguroglu, Johan Vansteenkiste, David R. Spigel, James Chih-Hsin Yang, Marcis Bajars, Mary Ruisi, Juliane Manitz, Fabrice Barlesi> ;Lung Cancer. 2021 Feb 6
• 307 citations
  Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
  Fabrice Barlesi, Johan Vansteenkiste, David R. Spigel, Hidenobu Ishii, Marina Chiara Garassino, Filippo de Marinis, Mustafa Ozguroglu, Aleksandra Szczesna, Andreas Pol...> ;The Lancet. Oncology. 2018 Nov 1
• 348 citations
  Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
  , , , , , , , , , , , , , , , , , , , , > ;Journal of Clinical Oncology. 2017 Jan 10
• 247 citations
  Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
  Jeffrey S. Weber, Geoff Gibney, Ryan J. Sullivan, Jeffrey A. Sosman, Craig L. Slingluff, Donald P. Lawrence, Theodore F. Logan, Lynn M. Schuchter, Suresh G. Nair Md, L...> ;The Lancet. Oncology. 2016 Jul 1
• 46 citations
  Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series
  Sowmya Ravi, Kristen Spencer, Mary Ruisi, Nageatte Ibrahim, Jason J. Luke, John A. Thompson, Keisuke Shirai, David H. Lawson, Heddy Bartell, Ragini R. Kudchadkar, Ngoc...> ;Journal for Immunotherapy of Cancer. 2014 Oct 14
• 105 citations
  Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.
  Sarah J. Barsam, Bethan Psaila, Marc Forestier, Lemke K. Page, Peter A. Sloane, Julia T. Geyer, Glynis O. Villarica, Mary M. Ruisi, Terry Gernsheimer, Juerg H. Beer, J...> ;Blood. 2011 May 26
• 19 citations
  Stability of measurement of the immature platelet fraction.
  Mary M. Ruisi, Bethan Psaila, Mary J. Ward, Glynnis Villarica, James B. Bussel> ;American Journal of Hematology. 2010 Aug 1
• Join now to see all

Abstracts/Posters

• Markedly Reduced Expression of Annexin A2 Is Associated with Hypofibrinolysis and Provoked and Unprovoked Venous Thromboembolism
  Mary Ruisi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019